HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy

The recent approval of clincially effective immune checkpoint inhibitors illustrates the potential of cancer immunotherapy. A challenging task remains the identification of specific targets guiding immunotherapy. Facilitated by technical advances, the direct identification of physiologically relevan...

Full description

Bibliographic Details
Main Authors: Peper, Janet Kerstin, Bösmüller, Hans-Christian, Schuster, Heiko, Gückel, Brigitte, Hörzer, Helen, Roehle, Kevin, Schäfer, Richard, Wagner, Philipp, Rammensee, Hans-Georg, Stevanović, Stefan, Fend, Falko, Staebler, Annette
Format: Online
Language:English
Published: Taylor & Francis 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910750/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910750/

Similar Items